Ibuprofen has been reported to possess anticancer activity. In the present work, four ibuprofen conjugates of resorcinarene-Polyamidoamine PAMAM-dendrimers were synthesized with eight or 16 ibuprofen moieties. The ibuprofen was released from the dendrimers in a dependent manner. The drug-conjugated nanoresorcinarene-dendrimers showed higher cellular uptake than free ibuprofen. In vitro cytotoxicity studies were performed with free ibuprofen and with the synthesized conjugates in U251, PC-3, K-562, HCT-15, MCF-7, SKLU-1, and MDA U251 (human glioblastoma), PC-3 (human prostatic adenocarcinoma), K-562 (human chronic myelogenous leukemia cells), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma), SKLU-1 (human lung adenocarcinoma), and MDA-MB-231 (human mammary adenocarcinoma) cancer cell lines by different cytotoxicity assays. Ibuprofen conjugates of the first and second generations showed significant cytotoxic effects towards the human glioblastoma (U251) and human mammary adenocarcinoma (MCF-7, MDA) cell lines. Moreover, the ibuprofen conjugates improved cytotoxicity compared to free ibuprofen. Increased therapeutic efficacy was observed with specific ibuprofen conjugates of the second generation using low doses.
Improving the activity and selectivity profile of anticancer agents will require designing drug carrier systems that employ soluble macromolecules. Olsalazine-PAMAM-dendrimer-salicylic acid-conjugates with dendritic arms of different lengths have shown good stability regarding the chemical link between drug and spacer. In this study, the drug release was followed in vitro by ultraviolet (UV) studies. Evaluation of the cytotoxicity of the olsalazine-PAMAM-dendrimer-salicylic acid-conjugates employing a sulforhodamine B (SRB) assay in PC-3 (human prostatic adenocarcinoma) and MCF-7 (human mammary adenocarcinoma) cell lines demonstrated that conjugate 9 was more active as an antiproliferative agent than cisplatin, and no cytotoxicity towards the African green monkey kidney fibroblast (COS-7) cell line was observed in any of the conjugates synthesized in the present work.
Dendrimers are highly branched three-dimensional macromolecules with a highly controlled structure, a single molecular weight, numerous controllable dendritic branches and peripheral functionalities, as well as the tendency to adopt an ellipsoid or spheroid shape once a certain size is reached. These features have made them attractive for application in pharmaceutical and medicinal chemistry in gene transfection, as medical imaging agents, and as drug carriers in potential drug delivery agents. The incorporation of metallic species into dendritic molecules has also been reported; the focus has been on organometallic dendrimers with metallic species only at specific positions of the molecules, such as the core, dendritic branches and the periphery, studied for their magnetic, electronic, and photo-optical or catalytic properties. Dendrimers have been investigated for optoelectronic applications (adsorption, emission, laser emission, nonlinear optics) through the encapsulation of active units by dendritic branches, core and peripheral. This review briefly discusses their use in nanomedicine, cancer treatment, treatment of other diseases, tissue repair, catalysis and applications in OLEDs and solar cells.
: A new class of dendrimers with open-resorcinarenes has been synthesized in good yields (77-85%). The open-resorcinarenes showed a high capacity for functionalization, having eight hydroxyl groups. The Williamson reaction with N,N-bis(2-azidoethyl)-2-bromo acetamide did not show any steric effect, obtaining sixteen azide terminal groups, which gave us the possibility to obtain a high molecular weight dendrimer via the azide-alkyne click reaction with prop-2-yn-1-yl-(ibuprofen)L-serinate derivatives to obtain the triazole ring spacers and the L-serinate(ibuprofen) derivatives as terminal groups. Also, we carried out the deprotection reaction of the L-serinate moiety terminal groups of the dendrimer 10 in good yields (95%). Three novel open-resorcinarene den-drimers with sixteen ibuprofen-L-serinate derivatives and hydroxyl, tert-butyl, and carboxylic acid; therefore, with three different terminal groups, with possible nanomedical activity are reported.
Aims: The aim of the present investigation was the synthesis of 3,5-bis(dodecyloxy)benzoate -PAMAM conjugates with indomethacin an mefenamic acid to examine their anticancer activity. background: The synthesis of conjugates with nonsteroidal anti-inflammatory drugs could be improve their activity with less toxicity and these compounds could be used for the treatment of cancer. objective: The synthesis of 3,5-bis(dodecyloxy)benzoate -PAMAM conjugates with indomethacin or mefenamic acid to examine their anticancer activity. method: The anticancer activity was studied of the conjugates against six human cancer cells U-251 (human glioblastoma), PC-3 (human prostatic adenocarcinoma), K-562 (human chronic myelogenous leukemia cells), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma), SKLU-1 (human lung adenocarcinoma) and the COS-7 African green monkey (as a control) cell lines. The conjugates with indomethacin and mefenamic acid were characterized by 1H, 13C NMR one- and two-dimension spectroscopy. result: All the conjugates synthetized with indomethacin or mefenamic acid showed anticancer activity against all the human cancer cell lines. The first generation of indomethacin conjugates showed better activity against PC-3 cell line than the second generation. But the second generation with indomethacin showed better activity against PC-3 (human prostatic adenocarcinoma) than the first generation. The second generation conjugate with mefenamic acid had strong selectivity to PC-3 (human prostatic adenocarcinoma) cells with IC50 value of 10.23±1.2 M in vitro. conclusion: In the paper, we report the synthesis and spectroscopic analyses of new indomethacin or mefenamic acid conjugates. The overall results showed that the conjugate of second generation with mefenamic acid could be a potential nanocarrier for human prostatic adenocarcinoma cancer treatment. other: our research will be continued
Background: Janus Dendrimer represents a novel class of synthetic nanocarriers. Since it is possible to introduce multiple drugs and target moieties, this helps the designing of new biocompatible forms with pharmacological activities comprised of different drugs with tailor-made functionalities, such as anticancer and nonsteroidal anti-inflammatory, which could improve the anticancer activity with less toxicity. Aims: This study aimed to determine the anticancer activity of the Janus dendrimers formed by two dendrons. One dendron conjugates with chlorambucil, and the other dendron conjugates with Ibuprofen. Methods: The cytotoxicity of the drug carriers was determined by the sulforhodamine B (SRB) assay for three cell lines. PC-3 (human prostatic adenocarcinoma), HCT-15 (human colorectal adenocarcinoma), MFC-7 (human breast cancer) and the COS-7 African green monkey kidney (used as a control) cell lines were seeded into 96-well plates at a density of 5x103 cells/well and cultured for 24 h before use. All the obtained compounds were characterized by 1H and 13C NMR one and two dimensions, UVvis, FTIR, MALDI-TOF, Electrospray mass, and FAB+. Microscopic images were taken in an Inverted microscope Nikon, Diaphot 300, 10x4 in culture medium. Results: Janus dendrimers (G1 and G2) were synthesized via an azide-alkyne click-chemistry reaction attaching on one face dendrons with ibuprofen molecules and, on the other face, attached a chlorambucil- derivative. The IC50 behavior of the conjugates of the first and second generations showed anticancer activity against PC-3, HCT-15, and MFC-7 cell lines. The second generation was more active against PC-3, HCT-15 and MFC-7 with IC50 of 3.8±0.5, 3.0±0.2 and 3.7 ± 1.1 mM, respectively Conclusion: The new Janus dendrimers with anticancer chlorambucil and nonsteroidal antiinflammatory Ibuprofen can improve the anticancer activity of chlorambucil with less toxicity. Future Prospects: Now, we are working on the synthesis of new Janus dendrimers using the most effective and fine methods. Moreover, we hope that we shall be able to obtain different generations that are more selective against cancer cells.